

Pittsburgh, PA 15213, USA
E-mail: kf0ft@andrew.cmu.edu

Gerhard Stöhrer
Risk Policy Center,
20 Stafford Place,
Larchmont, NY 10538, USA

Low-Level Radiation

It is hard to see what good taking another look at low-level radiation risk would do (ScienceScope, 27 Sept., p. 1787). Five previous reports have created nothing but controversy (1). In each report, one faction identified 0.1 Gray as the lower limit of acute and cancerous effects (1), only 100 times below the lethal dose and unchanged in 30 years of intense research. And each time a second faction insisted on exaggerating scientific uncertainty and creating artificial risks in order to "save lives." Hard numbers were usually buried under an inch of paper, but the frightening speculation appeared on page 1.

Not mentioned in those five reports is the important fact that radon has been safely regulated by a reasonable standard predating the Environmental Protection Agency (EPA) standard. That standard, still in use, corresponds to a cumulative dose only five times lower than the 0.1-Gray threshold (2). Yet surveys with exceptional statistical power show that this standard is safe (3).

References and Notes

1. *BEIR V: Health Effects of Exposure to Low Levels of Ionizing Radiation* (National Academy Press, Washington, DC, 1990).
2. Calculated from the 4 pico-Curies per liter action level for radon ["Technical support document for the 1992 Citizen's Guide to Radon" (EPA 400-R-92-011, Environmental Protection Agency, Washington, DC, 1992)]. The lowest carcinogenic dose in miners with an odds ratio greater than 3 is 226 working level months (WLM) [J. Sevc, *Health Phys.* **54**, 27 (1988)]. Conversion factor: 10 pico-Curies per liter per year = 2 WLM.
3. B. L. Cohen, *Health Phys.* **68**, 157 (1995).

Women Alcoholics at Bellevue, 1918–1919

Data published in *Science's* pages in a 1936 article about historical trends in alcoholism admissions at Bellevue Hospital in New York City are probably mistaken. The questionable data occur in a paper authored by alcoholism, vitamin, and cholesterol researcher Norman Jolliffe (1901–1961) ["The alcoholic admissions to Bellevue Hospital" **83**, 306 (1936)].

Jolliffe's paper reported a generally downward trend in the proportion of female (to male) Bellevue alcoholism admissions from 1902 to 1933—the latter, national prohibition's final year. The trend was punctuated however by a sudden spike in 1918 and 1919, when the proportion of female admissions virtually doubled to 41.8% and 39.5%, respectively. Jolliffe offered two guesses for the occurrence. First, it might have been "due in part to an increase of social drinking occasioned by entertaining soldiers embarking for and returning from overseas." Second, the unhappiness caused by the war-time absence of men turned more women to drink. Jolliffe cleverly deduced that the absence of men, and not worry about men's safety in combat, explained the rise, incidentally, by noting that female admissions were almost as large in 1919 as in 1918, even though hostilities had ceased by the latter year.

In 1990, I exchanged correspondence with the late Mark Keller, longtime editor of the *Journal of Studies on Alcohol*, who worked as Jolliffe's editorial and research assistant in the 1930s. Keller noted that a mixup had occurred in the collection of data for Jolliffe's Bellevue admissions paper. He explained that both of Jolliffe's hypotheses for the female admissions spike were moot because

Transgenic Mouse and Rat Production Services

Transgenic Animal Models and Production Services for Biomedical Research

- Custom Transgenic Model Development
- Transgenic Mouse and Rat Production
- Blastocyst Injection of ES Cells
- Transgenic Animal Breeding
- Cryopreservation Services
- Gene Expression Analysis
- Specific Pathogen Free Animals
- Shipments to Locations Worldwide



DNX Transgenics
303B College Rd. East
Princeton Forrestal Ctr.
Princeton, NJ 08540
(609) 520-0300 - Phone
(609) 520-9864 - Fax

Visit our WWW Pages at <http://www.dnxtrans.com>

DNX is the exclusive
commercial licensee for
U.S. Patent #4,873,191
DNA Zygote Microinjection



BIODIGM® Transgenic Animal Models

Transgenic Mouse Models Expressing Disease Related Genes

Cholesterol Metabolism:	Inflammation:
CETP	TNF α
ApoB 100	sPLA2
CETP/ApoB 100	TNF α /sPLA2
ApoE3 (arg112, cys142)	
CETP/ApoE3 (arg112, cys142)	

Our services are flexible to meet your transgenic animal needs.